Financial Performance - The company's operating revenue for Q1 2022 was ¥275,812,319.92, representing a year-on-year increase of 25.05%[6] - Net profit attributable to shareholders was ¥72,992,299.78, up 30.60% compared to the same period last year[6] - Total revenue for Q1 2022 reached ¥275,812,319.92, an increase of 25% compared to ¥220,556,420.82 in Q1 2021[33] - Operating profit for Q1 2022 was ¥86,046,623.34, compared to ¥64,889,101.32 in Q1 2021, representing a growth of 32%[33] - Net profit for Q1 2022 was 73,984,673.45 RMB, an increase from 55,889,458.14 RMB in Q1 2021, representing a growth of approximately 32.4%[36] - The total profit for the first quarter of 2022 was approximately ¥71.43 million, an increase of 32.3% compared to ¥54.01 million in the same period of 2021[52] Research and Development - R&D investment totaled ¥13,047,397.49, an increase of 71.33% year-on-year, accounting for 4.73% of operating revenue, up 1.28 percentage points[9] - Research and development expenses for Q1 2022 were ¥13,047,397.49, compared to ¥7,615,347.21 in Q1 2021, marking a significant increase of 71%[33] - The company's R&D expenses for Q1 2022 were CNY 11,526,211.91, compared to CNY 7,029,135.47 in Q1 2021, indicating a 64.1% increase[49] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,882,612,535.88, a 3.04% increase from the end of the previous year[9] - Total assets amounted to ¥1,882,612,535.88, up from ¥1,827,023,632.34 in the previous year[29] - The total liabilities decreased to ¥299,102,871.83 from ¥334,032,769.47, indicating a reduction of approximately 10%[29] - The total liabilities decreased to CNY 197,651,337.53 from CNY 265,273,659.04, a reduction of 25.5%[47] Cash Flow - The net cash flow from operating activities was negative at -¥2,177,816.55, indicating a cash outflow[6] - Operating cash flow for Q1 2022 was -2,177,816.55 RMB, an improvement compared to -4,222,809.62 RMB in Q1 2021[38] - Cash inflow from operating activities totaled ¥203.01 million, slightly down from ¥204.27 million in the previous year[55] - The company experienced a negative impact of ¥5.44 million from exchange rate fluctuations on cash and cash equivalents[55] Shareholder Information - The company had a total of 2,304 common shareholders at the end of the reporting period[13] - The total number of shares held by the top ten shareholders includes 1,130,301 shares held by Fidelity Fund (Hong Kong) Limited, indicating significant institutional interest[16] - The company has a total of 1,900,000 shares held by Zhejiang Merchants Securities Asset Management, which participated in strategic placement with a lock-up period of 12 months[19] Inventory and Receivables - The company reported a total of RMB 200,303,381.28 in inventory, slightly down from RMB 205,317,195.02, showing a decrease of about 2.4%[23] - Accounts receivable increased to RMB 338,806,783.88 from RMB 275,507,284.47, representing a growth of approximately 22.9%[23] - Accounts receivable increased significantly to CNY 344,415,207.98 from CNY 275,731,488.83, representing a growth of 24.9%[44] Equity - The total equity attributable to shareholders increased by 5.39% to ¥1,561,170,979.31 compared to the end of the previous year[9] - The company's equity attributable to shareholders increased to ¥1,561,170,979.31 from ¥1,481,337,775.34, a rise of about 5.4%[29] - The total equity increased to CNY 1,558,611,434.62 from CNY 1,480,343,119.40, reflecting a growth of 5.3%[49] Accounting Policies - The company adjusted its accounting policy, resulting in an increase in operating costs from RMB 128,306,856.13 to RMB 130,623,661.22, an adjustment impact of RMB 2,316,805.09[20] - The company’s sales expenses were adjusted from RMB 10,135,598.93 to RMB 7,818,793.84 due to the accounting policy change, reflecting a reduction of approximately 22.5%[20] - The company has not applied the new accounting standards for the first quarter of 2022[58]
宏华数科(688789) - 2022 Q1 - 季度财报